| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sozinibercept | OPT-302; VGX-300 | Phase 3 Clinical | Orphan Europe Sarl | Neovascularization, Pathologic; Retinal Diseases; Diabetic macular oedema; Retinal Degeneration; Eye Diseases; Macular Degeneration | Details |
| VEGF-C gene therapy (Herantis Pharma) | LX-1101; Ad-VEGF-C | Phase 2 Clinical | Herantis Pharma | Lymphedema | Details |
| IBI-333 | IBI-333 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Wet Macular Degeneration; Macular Degeneration | Details |




